Causes of dysregulation of lipid metabolism in chronic renal failure

Seminars in Dialysis

Volumn 22, Issue 6, 2009, Pages 644-651

  Vaziri, Nosratola D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN;

ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DYSLIPIDEMIA; HUMAN; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; UREMIA;

CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; DYSLIPIDEMIAS; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS; OXIDATIVE STRESS; RENAL DIALYSIS; UREMIA;

EID: 71549131675     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2009.00661.x     Document Type: Article

References (63)

1. Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D, Grimm R, Liu J, Louis T, Manning W, Matas A, McBean M, Murray A, St Peter W, Xue J, Fan Q, Guo H, Li S, Li S, Roberts T, Snyder J, Solid C, Wang C, Weinhandl E, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Johnson R, Sheets D, Forrest B, Berrini D, Constantini E, Everson S, Frederick P, Eggers P, Agodoa L : United States Renal Data System. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 45 (1 Suppl. 1 A5 A7, S1-280, 2005
2. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM : The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62 : 1524 1538, 2002
3. McCullough PA : Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J Am Coll Cardiol 41 : 725 728, 2003
4. Stenvinkel P, Alvestrand A : Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 15 : 329 337, 2002
5. Vaziri ND : Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis 38 : S74 S79, 2001
6. Vaziri ND : Oxidative stress in chronic renal failure: the nature, mechanism and consequences. Semin Nephrol 24 : 469 473, 2004
7. Vaziri ND, Ni Z, Wang XQ, Oveisi F, Zhou XJ : Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol Renal Physiol 274 : F642 F649, 1998
8. Vaziri ND : Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am J Physiol Renal Physiol 290 : 262 272, 2006
9. Vaziri ND, Moradi H : Mechanism of dyslipidemia of chronic renal failure. Hemodial Int 10 : 1 7, 2006
10. Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P : Dialysis modalities and dyslipidemia. Kidney Int Suppl 84 : S110 S112, 2003
11. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ : Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 35 : 852 862, 2000
12. Vaziri ND, Liang KH : Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 48 : 1979 1985, 1995
13. Vaziri ND, Sato T, Liang K : Molecular mechanism of altered cholesterol metabolism in focal glomerulosclerosis. Kidney Int 63 : 1756 1763, 2003
14. Rader DJ : Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116 : 3090 3100, 2006
15. Kaysen GA : Hyperlipidemia in chronic kidney disease. Int J Artif Organs 30 : 987 992, 2007
16. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM : Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108 : 2751 2756, 2003
17. Fielding CJ, Fielding PE : Cellular cholesterol efflux. Biochim Biophys Acta 1533 : 175 189, 2001
18. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF : The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 104 : R25 R31, 1999
19. Oram JF : Tangier disease and ABCA1. Biochim Biophys Acta 1529 : 321 330, 2000
20. Oram JF, Vaughan AM : ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res 99 : 1031 1043, 2006
21. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M : Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271 : 518 520, 1996
22. Fabre AC, Vantourout P, Champagne E, Tercé F, Rolland C, Perret B, Collet X, Barbaras R, Martinez LO : Cell surface adenylate kinase activity regulates the F (1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes. Cell Mol Life Sci 63 : 2829 2837, 2006
23. Attman PO, Samuelsson O, Alaupovic P : Lipoprotein metabolism and renal failure. Am J Kidney Dis 21 : 573 592, 1993
24. Vaziri ND, Deng G, Liang K : Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 14 : 1462 1466, 1999
25. Shao B, Oda MN, Oram JF, Heinecke JW : Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 21 : 322 328, 2006
26. Moradi H, Pahl MV, Elahimehr R, Vaziri ND : Impaired antioxidant activity of HDL in chronic kidney disease. Transl Res 153 : 77 85, 2009
27. Zhao Y, Marcel YL : Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins. Biochemistry 35 : 7174 7180, 1996
28. Shoji T, Nishizawa Y, Nishitani H, Billheimer JT, Sturley SL : Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 41 : 1653 1661, 1992
29. Liang K, Kim C, Vaziri ND : HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Am J Physiol Renal Physiol 288 : F539 F544, 2005
30. Vaziri ND, Liang K, Parks JS : Downregulation of lecithin: cholesterol acyltransferase (LCAT) in chronic renal failure. Kidney Int 59 : 2192 2196, 2001
31. Kimura H, Miyazaki R, Suzuki S, Gejyo F, Yoshida H : Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients. Am J Kidney Dis 38 : 70 76, 2001
32. Kimura H, Miyazaki R, Imura T, Masunaga S, Suzuki S, Gejyo F, Yoshida H : Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney Int 64 : 1829 1837, 2003
33. Pahl MV, Ni Z, Sepassi L, Vaziri ND : Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin: cholesterol acyltransferase in end-stage renal disease. Nephrol Dial Transplant 24 : 2541 2546, 2009
34. De Sain-van der Velden MG, Rabelink TJ, Reijngoud DJ, Gadellaa MM, Voorbij HA, Stellaard F, Kaysen GA : Plasma alpha 2 macroglobulin is increased in nephrotic patients as a result of increased synthesis alone. Kidney Int 54 : 530 535, 1998
35. Vaziri ND : Molecular mechanisms of lipid dysregulation in nephrotic syndrome. Kidney Int 63 : 1964 1976, 2003
36. Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG : Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest 97 : 2167 2173, 1996
37. Liang K, Vaziri ND : Downregulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int 51 : 1933 1937, 1997
38. Sato T, Liang K, Vaziri ND : Protein restriction and AST-120 improve lipoprotein lipase, hepatic lipase and VLDL receptor deficiencies in focal glomerulosclerosis. Kidney Int 64 : 1780 1786, 2003
39. Liang K, Vaziri ND : Downregulation of hepatic high-density lipoprotein receptor, SRB-1 in nephrotic syndrome. Kidney Int 56 : 621 626, 1999
40. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezón E, Champagne E, Pineau T, Georgeaud V, Walker JE, Tercé F, Collet X, Perret B, Barbaras R : Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 421 : 75 79, 2003
41. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM : HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21 : 481 488, 2001
42. Bagdade JD, Porte D Jr., Bierman EL : Hypertriglyceridemia: a metabolic consequence of chronic renal failure. N Engl J Med 279 : 181 185, 1968
43. Chan MK, Varghese Z, Moorhead JF : Lipid abnormalities in uremia, dialysis, and transplantation. Kidney Int 19 : 625 637, 1981
44. Heuck CC, Liersch M, Ritz E, Stegmeier K, Wirth A, Mehls O : Hyperlipoproteinemia in experimental chronic renal insufficiency in the rat. Kidney Int 14 : 142 150, 1978 (Pubitemid 8406446)
45. Majumdar A, Wheeler DC : Lipid abnormalities in renal disease. J R Soc Med 93 : 178 182, 2000
46. Chan MK, Persaud J, Varghese Z, Moorhead JF : Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int 25 : 812 818, 1984
47. Sakurai T, Oka T, Hasegawa H, Igaki N, Miki S, Goto T : Comparison of lipids, apoproteins and associated enzyme activities between diabetic and nondiabetic end-stage renal disease. Nephron 61 : 409 414, 1992
48. Vaziri ND, Liang K : Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 50 : 1928 1935, 1996 (Pubitemid 26417536)
49. Vaziri ND, Wang XQ, Liang K : Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol 273 : F925 F930, 1997
50. Akmal M, Kasim SE, Soliman AR, Massry SG : Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 37 : 854 858, 1990
51. Herz J, Strickland DK : LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 108 : 779 784, 2001
52. Kim C, Vaziri ND : Downregulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int 67 : 1028 1032, 2005
53. Takahashi S, Warabayasi Y, Nakai T, Sakai J, Yamamoto T : Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A 89 : 9252 9256, 1992
54. Vaziri ND, Liang K : Down-regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int 51 : 913 919, 1997 (Pubitemid 27157982)
55. Liang K, Oveisi F, Vaziri ND : Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int 53 : 626 630, 1998
56. Vaziri ND, Dang B, Zhan CD, Liang K : Downregulation of hepatic Acyl-CoA: diglycerol acyltransferase (DGAT) in chronic renal failure. Am J Physiol Renal Physiol 287 : F90 F94, 2004
57. Vaziri ND, Kim CH, Phan D, Kim S, Liang K : Upregulation of acyl-CoA: diacylglycerol acyltransferase (DGAT) expression in nephrotic syndrome. Kidney Int 66 : 262 267, 2004
58. Liang K, Vaziri ND : Gene expression of LDL receptor, HMG-CoA reductase and cholesterol-7α-hydroxylase in chronic renal failure. Nephrol Dial Transplant 12 : 1381 1386, 1997
59. Vaziri ND, Liang K : Downregulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 50 : 887 893, 1996
60. Liang K, Vaziri ND : Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure. Am J Physiol Endocrinol Metab 283 : E676 E681, 2002
61. Vaziri ND, Liang K : ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure. Am J Physiol Renal Physiol 287 : F1038 F1043, 2004
62. Krane V, Winkler K, Drechsler C, Lilienthal J, März W, Wanner C, German Diabetes and Dialysis Study Investigators : Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 74 : 1461 1467, 2008
63. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators : Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 21 353 : 238 248, 2005 (Pubitemid 41058323)